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Abstract
Background: Although many factors and molecules that are closely associated with non-alcoholic fatty liver
disease (NAFLD)/non-alcoholic steatohepatitis (NASH) have been reported, the role of endothelial nitric oxide
synthase (eNOS)-derived nitric oxide (NO) in the pathogenesis of NAFLD/NASH remains unclear. We therefore
investigated the role of eNOS-derived NO in NAFLD pathogenesis using systemic eNOS-knockout mice fed a
high-fat diet.
Methods: eNOS-knockout and wild-type mice were fed a basal diet or a high-fat diet for 12 weeks. Lipid
accumulation and inflammation were evaluated in the liver, and various factors that are closely associated with
NAFLD/NASH and hepatic tissue blood flow were analyzed.
Results: Lipid accumulation and inflammation were more extensive in the liver and lipid accumulation was less
extensive in the visceral fat tissue in eNOS-knockout mice, compared with wild-type mice, after 12 weeks of being fed a
high-fat diet. While systemic insulin resistance was comparable between the eNOS-knockout and wild-type mice fed a
high-fat diet, hepatic tissue blood flow was significantly suppressed in the eNOS-knockout mice, compared with the
wild-type mice, in mice fed a high-fat diet. The microsomal triglyceride transfer protein activity was down-regulated in
eNOS-knockout mice, compared with wild-type mice, in mice fed a high-fat diet.
Conclusions: A deficiency of eNOS-derived NO may exacerbate the early-stage of NASH pathogenesis by changing
the fat distribution in a mouse model via the regulation of hepatic tissue blood flow.
Keywords: NO, NAFLD, Hepatic tissue blood flow, Fat distribution, Obese mice
Background
Non-alcoholic fatty liver disease (NAFLD) is one of the
most important causes of chronic liver disease and is as-
sociated with systemic insulin resistance (IR) and meta-
bolic syndrome. NAFLD includes non-alcoholic fatty
liver (NAFL) and non-alcoholic steatohepatitis (NASH);
NAFL represents the first phase of NASH, which is
characterized by steatosis, and can then develop into
fatty liver disease with associated inflammation [1].
NASH is thought to lead to liver fibrosis, cirrhosis, and
hepatocellular carcinoma, resulting in increased morbid-
ity and mortality. The pathogenesis of NAFLD remains
to be clarified fully.
We previously reported that several potential mecha-
nisms are involved in the pathogenesis of NAFLD [2–4].
However, other factors associated with NAFLD progres-
sion remain to be determined.
Nitric oxide (NO) is a gas produced by nitric oxide
synthase (NOS) enzyme [5], and three major isoforms of
NOS are known to exist: neuronal NOS (nNOS), indu-
cible NOS (iNOS), and endothelial NOS (eNOS). eNOS-
derived NO is known to have important endothelial
functions, including the regulation of vascular tone and
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regional blood flow [6]. On the other hand, liver steato-
sis has been shown to be associated with sinusoidal nar-
rowing and a reduction in sinusoidal flow; furthermore,
microvascular changes may contribute to progressive
liver injury in metabolic forms of steatohepatitis [7].
Chronic NOS inhibition has been reported to accelerate
NAFLD progression [8]; however, the roles of eNOS and
generated NO in the pathogenesis of NAFLD/NASH
have not yet been fully elucidated in eNOS knockout
(eNOS-/-) mice fed a high-fat diet (HFD).
In this study, we investigated the role of eNOS-derived
NO in the pathogenesis of NAFLD using systemic
eNOS-knockout mice fed an HFD.
Methods
Animal treatment and procedures
We purchased a C57BL/6J backcrossed C57BL/6J-
Nos3tm1Lau colony from Jackson Labs (Bar Harbor, ME
04609, USA) to create male congenic wild-type (eNOS
+/+) and eNOS knockout (eNOS-/-) mice. Mice were
allowed free access to food and tap water throughout
the acclimatization and experimental periods.
Beginning at 6 weeks of age, each strain of mice was
fed a basal diet (BD) or an HFD. Thirty-two mice were
divided into 4 groups: (1) eNOS+/+ and BD; (2) eNOS-/-
and BD; (3) eNOS+/+ and HFD; and (4) eNOS-/- and
HFD. After a 12-week experimental period, eight mice
in each group were examined after being subjected to an
overnight fast. The HFD consisted of high-fat diet 32,
containing 20 % protein, 60 % fat, and 20 % carbohy-
drate, in powdered form from Japan CLEA (Tokyo,
Japan), while the BD consisted of MF, containing 22 %
protein, 6 % fat, and 47 % carbohydrate, from Oriental
Yeast Co., Ltd. (Tokyo, Japan). The precise contents of
these feeds have been described previously [4]. All the
animals were treated humanely according to the guide-
lines of the National Institutes of Health and the AERI-
BBRI Animal Care and Use Committee. The animal pro-
tocols were approved by the Yokohama City University
Medical School guidelines for the care and use of labora-
tory animals. This study was conducted by the approval
of the institutional review board at the Yokohama City
University Medical School.
Measurement of plasma and serum biochemical markers
Serum alanine aminotransferase (ALT) was measured using
Spotchem SP-4410 (Arklay Co., Kyoto, Japan). The total
serum cholesterol (Chol) and triglyceride (TG) levels were
analyzed using an online dual-enzymatic method for the
simultaneous quantification of cholesterol and TG using
high-performance liquid chromatography according to a
previously described procedure [4, 9, 10]. The fasting
plasma glucose level and the serum levels of fasting insulin,
leptin, adiponectin, and non-esterified fatty acid (NEFA)
were determined using a Glutest Pro kit (Sanwa Kagaku
Kenkyusyo Co., Nagoya, Japan), an Ultra Sensitive Insulin
ELISA kit (Biochemical Research Laboratory, Morinaga
Milk Industry Co., Tokyo, Japan), an ELISA Mouse Leptin
kit (Biochemical Research Laboratory, Morinaga Milk In-
dustry Co., Tokyo, Japan), a Mouse/Rat Adiponectin ELISA
kit (Otsuka Pharmaceutical Co., Tokyo, Japan), and a NEFA
C-Test kit (Wako Pure Chemical Industries Co., Osaka,
Japan), respectively. The blood IR was estimated using the
homeostasis model assessment of IR (HOMA-IR) and the
following equation: IR = fasting plasma glucose level (mg/
dL) × fasting serum insulin level (ng/mL)/22.5.
Insulin tolerance test (ITT)
Mice were fed ad libitum prior to being subjected to a
fast immediately before the start of the study. The mice
were intraperitoneally challenged with 0.75 mU/g body
weight of human insulin (Novolin R; Novo Nordisk,
Denmark). Blood samples were then collected to meas-
ure the glucose levels at 0, 30, 60, 80, 100, and 120 min
after the insulin injection [11].
Measurement of liver triglyceride content
The liver samples were homogenized in 50 mM Tris/HCl
buffer, pH7.4, containing 150 mM NaCl, 1 mM EDTA,
and 1 mM PMSF. The liver TG levels were analyzed enzy-
matically using a diagnostic kit (Infinity™; Thermo DMA,
Arlington, TX, USA).
Liver MTP activity assay
MTP activity was measured using an MTP assay kit
(Roar Biochemical, New York, NY, USA), according to a
previously described method [12, 13].
CT scanning
In the 12-week model, the abdomen of each mouse was
scanned prior to sacrifice using an X-ray computed tom-
ography (CT) system (eXplore Locus; GE Healthcare
Bio-Sciences GK, Tokyo, Japan) developed for small
experimental animals [14]. The mice were anesthetized
for the duration of the scan, and non-contrast CT scan-
ning was performed.
Measurement of liver/spleen ratio of CT values and
visceral fat volume
The hepatic attenuation index was obtained using non-
contrast CT images to determine the liver-to-spleen at-
tenuation ratio [15]. The inverse of the liver-to-spleen
density ratio was regarded as an indicator of the degree
of fat infiltration in the liver [16]. The visceral fat vol-
ume was quantified using CT imaging [17, 18].
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Determination of Hepatic Tissue Blood Flow
At 12 weeks, each mouse was anesthetized and a lapar-
otomy was conducted to determine the hepatic tissue
blood flow at several points located 1 mm from the edge
of the right or left lobe using a noncontact-type laser
Doppler blood flow meter (OMEGAFLO FLO-N1;
OMEGAWAVE Inc., Tokyo, Japan) [19, 20]. The mea-
surements were performed at 3 different points in each
of the right and left lobes. The mean of the three values
for each lobe was calculated, and the resulting values
were expressed as a percentage of the value obtained in
the eNOS+/+ and BD group.
Liver histopathological and immunohistochemical
evaluations
Liver samples were excised and embedded in Tissue-Tek
OCT compound (Sakura Finetek USA Inc., Torrance, CA,
USA) and paraffin for the histological analysis. Formalin-
fixed and paraffin-embedded sections were processed
routinely using hematoxylin and eosin (H&E), myeloper-
oxidase (MPO), naphthol AS-D chloroacetate esterase
[21] and Sirius-red. To evaluate the fat deposition, the
OCT-embedded samples were stained with oil-red O.
Liver histology and scoring systems
All the histopathological findings were scored by the
same pathologists (Y.N. and S.M.), who were unaware of
the treatments that the animals had received. The histo-
logical features were grouped into 3 broad categories
(steatosis, inflammation, and fibrosis) to enable the use
of the NAFLD activity score (NAS) [22]. The evaluation
protocol, which has been described previously [23], is
detailed in Table 3.
RNA isolation and reverse transplantation
Total RNA was isolated from the samples using an
RNeasy Mini kit (Qiagen GmbH, Hilden, Germany; Cat
No. 74126); reverse transcription was then performed to
produce cDNA using a TaqMan Gold RT-PCR Kit (Ap-
plied Biosystems, Foster City, CA, USA) according to the
manufacturer’s instructions, as previously described [4].
Quantification of gene expressions using real-time RT-PCR
The hepatic mRNA levels of several markers, as well as the
housekeeping gene β-actin, in the liver tissues were deter-
mined using fluorescence-based real-time RT-PCR and an
ABI PRISM 7700 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA). Real-time RT-PCR was
performed using the TaqMan and Power SYBR Green
PCR Master Mix reagent, according to the manufacturer’s
instructions (Applied Biosystems, Foster City, CA, USA).
The values were normalized to the expression level of the
endogenous control, β-actin. The gene expression ratio was
determined using data from the eNOS+/+ and BD group
mice as the control group. The probe and primer pair spe-
cific for β-actin were purchased from Applied Biosystems.
The primer sequences of sterol regulatory element binding
protein-1c (SREBP-1c), peroxisome proliferators-activated
receptor alpha1 (PPAR-α1), nNOS, and iNOS are listed in
Table 1.
Statistical analysis
The statistical analyses were performed using SPSS for
Windows, version 12 (IBM Co. Armonk, NY, USA). All
the results were expressed as the mean ± SEM. Statistical
comparisons were made using the Student t-test or
Scheffe’s method after an analysis of variance (ANOVA).
A value of P < 0.05 was considered statistically significant.
Results
HFD feeding induced the phenotype of metabolic
syndrome and the pathogenesis of early-stage NASH
After 12 weeks of HFD feeding, the eNOS+/+ and HFD
mice had significantly higher body weights, liver weights,
and visceral fat weights than the control mice (eNOS+/+
and BD) (Table 2). The eNOS+/+ and HFD mice showed
signs of insulin resistance and dyslipidemia (Table 2 and
Fig. 4a), thus demonstrating the phenotype of metabolic
syndrome. Furthermore, hepatic steatosis and very mild
inflammation were observed in the eNOS+/+ and HFD
mice, which were considered to have early-stage NASH
(Table 3 and Figs. 1a, 2a-d). The reason for the negative
findings of the liver tissue MPO staining examination
might be related to the model used in this study for early-
stage NASH, which showed very mild inflammation, such
as very small inflammatory foci detected in the H-E
stained samples (Fig. 2d). No apparent signs of liver fibro-
sis were observed in any of the groups (Fig. 2e).
Deficiency of eNOS-derived NO increased lipid deposits in
the liver and decreased the visceral fat volume in HFD-fed
mice
In the NAFLD/NASH model, an increase in the body
weight was observed after 12 weeks of HFD feeding, and
no significant difference was observed between the eNOS
+/+ and HFD mice and the eNOS-/- and HFD mice
(Table 2). The eNOS-/- and HFD mice had a significantly
higher liver weight and a significantly lower visceral fat
weight than then eNOS+/+ and HFD mice; furthermore,
the eNOS-/- and HFD mice had a significantly higher liver
weight/body weight ratio and a significantly lower visceral
fat weight/body weight ratio, compared with the eNOS+/+
and HFD mice (Table 2).
As an indicator of the degree of fat infiltration in the
liver, the liver-to-spleen attenuation ratio obtained using
non-contrast CT images showed that hepatic steatosis
was significantly severer in the eNOS-/- and HFD mice
than in the eNOS+/+ and HFD mice (Fig. 1a).
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The visceral fat volume as quantified using CT im-
aging was significantly lower in the eNOS-/- and HFD
mice than in the eNOS+/+ and HFD mice (Fig. 1b).
An analysis of the parameters associated with metabolic
syndrome showed no significant differences between the
eNOS+/+ and HFD mice and the eNOS-/- and HFD mice
when the fasting plasma glucose level, fasting insulin level,
HOMA-IR, serum TG level, serum NEFA level, and
serum leptin level were compared. However, the serum
cholesterol level was significantly higher in the eNOS-/-
and HFD mice than in the eNOS+/+ and HFD mice
(Table 2).
Deficiency of eNOS-derived NO exacerbated the
pathogenesis of early-stage NASH in HFD-fed mice
Pathological examination of the liver showed that the
eNOS-/- and HFD mice had severer hepatic steatosis
and inflammation than the eNOS+/+ and HFD mice
(Fig. 2a and 2c). The liver TG content and the serum
ALT levels were significantly higher in the eNOS-/- and
HFD mice than in the eNOS+/+ and HFD mice (Fig. 2b
and Table 2). The liver tissue MPO and Sirius red stain-
ing examinations showed no significant positive findings
(Fig. 2d and 2e), and the additional liver tissue naphthol
AS-D chloroacetate esterase staining examination
showed negative findings (data not shown). An analysis
of the histological scores for the livers using NAS
showed that the scores for the steatosis grade were sig-
nificantly higher in the eNOS-/- and HFD mice than in
the eNOS+/+ and HFD mice; these results were consist-
ent with the results of the CT scan examination. Fur-
thermore, the scores for lobular inflammation and liver
cell injury were significantly higher for the eNOS-/- and
HFD mice than for the eNOS+/+ and HFD mice
(Table 3).
Deficiency of eNOS-derived NO decreased the hepatic
tissue blood flow
Measurement of the hepatic tissue blood flow using a
noncontact-type laser Doppler blood flow meter showed
that a deficiency of eNOS-derived NO significantly de-
creased the hepatic tissue blood flow in both hepatic
lobes under each dietary condition (Fig. 3). HFD feeding
was also shown to significantly decrease the hepatic
blood flow, since the value for the eNOS+/+ and HFD
Table 1 Primer sequences used for real-time PCR analysis





Table 2 Characteristics of mice in the 12-week model
12-week model
eNOS+/+BD eNOS-/-BD eNOS+/+HFD eNOS-/-HFD
Number of animals 8 8 8 8
Body weight (g) 28.1 ± 1.9 27.2 ± 2.4 42.8 ± 3.1* 41.7 ± 2.4
Liver weight (g) 1.2 ± 0.1 1.2 ± 0.2 2.3 ± 0.6* 2.8 ± 0.5§
Visceral fat weight (g) 0.6 ± 0.1 0.7 ± 0.3 2.0 ± 0.3* 1.2 ± 0.3§
Liver weight/body weight ratio (%) 4.2 ± 0.3 4.3 ± 0.6 5.2 ± 1.0* 6.7 ± 1.0§
Visceral fat weight/body weight ratio (%) 2.1 ± 0.4 2.4 ± 1.0 4.7 ± 1.0* 3.0 ± 0.6§
Serum ALT (IU/L) 9.2 ± 0.8 17.5 ± 9.3 74.8 ± 41.4* 172.8 ± 58.2§
Fasting glucose (mg/dL) 89.6 ± 8.0 85.7 ± 20.6 151.8 ± 36.4* 135.8 ± 32.3
Fasting insulin (ng/mL) 0.72 ± 0.41 0.57 ± 0.72 1.63 ± 0.81* 2.10 ± 0.74
HOMA-IR 2.9 ± 1.8 2.0 ± 2.5 11.0 ± 6.7* 13.3 ± 6.6
Serum cholesterol (mg/dL) 90.5 ± 3.8 85.1 ± 4.9 174.8 ± 22.9* 263.0 ± 28.5§
Serum TG (mg/dL) 24.8 ± 6.8 26.0 ± 5.6 31.3 ± 5.9* 33.8 ± 8.2
Serum NEFA (mEq/L) 1.2 ± 0.0 1.1 ± 0.2 1.8 ± 0.1* 1.7 ± 0.3
Serum leptin (ng/mL) 3.9 ± 2.0 3.5 ± 2.7 30.2 ± 4.4* 31.6 ± 22.9
BD basal diet, HFD high-fat diet, HOMA-IR homeostasis model assessment of insulin resistance, TG triglyceride, NEFA nonesterified fatty acid
Data are expressed as the mean ± SEM
Significant differences exist between *eNOS+/+ and BD vs. eNOS+/+ and HFD; §eNOS+/+ and HFD vs. eNOS-/- and HFD for listed parameters at the P < .05 level
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mice was significantly lower than that of the eNOS+/+
and BD mice (Fig. 3).
Comparison of the mechanism associated with the
pathogenesis of NAFLD between wild-type and
eNOS-knockout mice under HFD conditions
The ITT results at 12 weeks showed no significant
difference in the systemic response to insulin injection
between the eNOS+/+ and HFD mice and the eNOS-/-
and HFD mice, while it was significantly lower in the
eNOS+/+ and HFD mice than in the eNOS+/+ and BD
mice (Fig. 4a).
An analysis of the liver mRNA expression levels showed
that no significant differences in the liver mRNA levels of
SREBP-1c and PPAR-α1 were observed between the eNOS
+/+ and HFD mice and the eNOS-/- and HFD mice. Fur-
thermore, the liver MTP activity level was significantly
down-regulated in the eNOS-/- and HFD mice, compared
with the eNOS+/+ and HFD mice (Fig. 4b). As for the liver
mRNA levels of other isoforms of NOS, no significant
differences in the levels of either nNOS or iNOS were ob-
served between the eNOS+/+ and HFD mice and the
eNOS-/- and HFD mice (data not shown).
Discussion
NAFLD/NASH is presently the most common chronic
liver disorder, displaying a wide spectrum of liver damage
ranging from simple steatosis to steatohepatitis, advanced
fibrosis, and cirrhosis. NAFLD/NASH is a complex dis-
ease with no simple causes. A new disease model has been
proposed suggesting that multiple hits may act in parallel,
resulting in liver inflammation; this model is known as the
multiple parallel hits hypothesis [24]. A relationship be-
tween fatty liver changes and hepatic microcirculation has
Table 3 Histological Scores of Livers using the NAFLD activity score (NAS)11)
12-week model
Item Definition Score eNOS+/+ eNOS-/- eNOS+/+ eNOS-/-
BD BD HFD HFD
Steatosis
Grade Parenchymal involvement
<5 % 0 8 8 0 0
5%-33 % 1 0 0 6 2
33%-66 % 2 0 0 2 6
>66 % 3 0 0 0 0
Average 0.00 0.00 1.25* 1.75§
Inflammation
Lobular inflammation Assessment of all inflammatory foci
No foci 0 8 8 5 1
<2 foci per 200 × field 1 0 0 3 7
2-4 foci per 200 × field 2 0 0 0 0
>4 foci per 200 × field 3 0 0 0 0
Liver cell injury Ballooning
None 0 8 8 0 0
Few balloon cells 1 0 0 8 8
Many cells/prominent ballooning 2 0 0 0 0
Average 0.00 0.00 1.38* 1.88§
Fibrosis
Stage Method of Brunt
None 0 8 8 8 8
Perivenular/perisinusoidal fibrosis 1 0 0 0 0
Combine pericellular portal fibrosis 2 0 0 0 0
Septal/bridging fibrosis 3 0 0 0 0
Cirrhosis 4 0 0 0 0
Average 0.00 0.00 0.00 0.00
BD basal diet, HFD high fat diet
Significant differences exist between *eNOS+/+ and BD vs. eNOS+/+ and HFD; §eNOS+/+ and HFD vs. eNOS-/- and HFD for listed parameters at the P < .05 level
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been described in several studies [25, 26]. Moreover, an-
other study demonstrated that key signaling molecules
mediating the metabolic actions of insulin were necessary
for insulin to stimulate the production of NO and vaso-
dilatation in human vascular endothelium [27]. Thus, we
focused on the role of the eNOS gene in the pathogenesis
of NAFLD/NASH; NO, produced by various isoforms of
NOS, is an ubiquitous signaling molecule involved in the
regulation of metabolic homeostasis, and eNOS, which
the endothelium produces as a vasoactive substance, has
been shown to serve important functions, including the
regulation of regional blood flow, insulin resistance, and
energy production [6, 28].
In the present study, we used an HFD-induced
NAFLD/NASH mouse model with or without the eNOS
gene. In our NAFLD/NASH model using HFD condi-
tions, prominent hepatic steatosis and very mild liver in-
flammation were observed after 12 weeks, but typical
fibrosis was not observed. In this “early-stage NAFLD/
NASH” model, eNOS-derived NO changed the fat distri-
butions in the liver and viscera of the mice. eNOS-
knockout mice reportedly exhibit a clustering of symp-
toms belonging to the metabolic syndrome phenotype,
such as body weight gain, hypertension, insulin resistance,
and dyslipidemia [29]. These parameters of eNOS-knock-
out mice and wild-type mice reportedly differ according
Fig. 1 Analysis of liver weight, lipid deposits in the liver, and visceral fat volume. a The liver-to-spleen attenuation ratio obtained using non-contrast CT
images showed that hepatic steatosis was significantly severer in the eNOS-/-/HFD mice than in the eNOS+/+/HFD mice at 12 weeks. b The visceral fat
volume quantified in the CT imaging of the eNOS-/-/HFD mice was significantly lower than that of the eNOS+/+/HFD mice at 12 weeks. (Data were
expressed as the mean ± SEM. *P < 0.05, represents a significant difference; n.s. represents no significant difference.)
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Fig. 2 Analysis of liver steatosis and inflammation. a Oil-red O staining (red color) shows lipid deposits in liver samples. At 12 weeks, macrovesicular
steatosis was visible in the eNOS-/-/HFD mice and microvesicular steatosis was visible in the eNOS+/+/HFD mice. Scale bar, 200 μm. b The liver TG
content was significantly higher in the eNOS-/-/HFD mice than in the eNOS+/+/HFD mice. The liver TG content was significantly higher in the eNOS
+/+/HFD mice than in the eNOS+/+/BD mice, which were regarded as the control group. c Liver samples stained using H&E. An evaluation of the
number of inflammatory foci per field and the amount of ballooning revealed that the eNOS-/-/HFD mice exhibited severer liver inflammation than
the eNOS+/+/HFD mice at 12 weeks. Scale bar, 200 μm. d and e Liver samples stained using myeloperoxidase (d) and Sirius red (e) showed no
significant positive findings. (Data were expressed as the mean ± SEM. *P < 0.05, represents a significant difference; n.s. represents no
significant difference.)
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to diet, sex, and the study period [28–34]. In both the
eNOS-knockout mice and the wild-type mice fed an HFD
during the 12 weeks of our study period, obesity, insulin
resistance, dyslipidemia and high serum leptin levels were
observed, although these markers were comparable be-
tween the eNOS-knockout and the wild-type mice fed an
HFD, with the exception of the serum cholesterol level.
Hepatic steatosis and the increases in the serum ALT
levels were significantly severer in the eNOS-knockout
mice fed an HFD than in the wild-type mice fed an HFD,
while the visceral fat volume was significantly lower in the
eNOS-knockout mice fed an HFD, compared with the
wild-type mice fed an HFD in this study.
The mechanism responsible for the changes in fat
distribution in the liver and viscera of eNOS-knockout
mice fed an HFD may be associated with the hepatic
blood flow. Actually, eNOS-knockout mice fed an HFD
exhibited a significantly lower hepatic tissue blood flow,
compared with wild-type mice fed an HFD, with no sig-
nificant difference in systemic insulin clearance observed
between the eNOS-knockout mice and the wild-type
mice fed an HFD. These results suggested that eNOS
may play an important role in the progression of “early-
stage NAFLD/NASH” not through insulin resistance,
but through direct hepatic vascular action under the
HFD condition. An analysis of factors associated with
lipid metabolism in the liver showed that the liver MTP
activity level was significantly lower in the eNOS-knock-
out mice fed an HFD than in the wild-type mice fed an
HFD. MTP is a heterodimeric lipid transfer protein that
is essential for very low density lipoprotein synthesis and
transfer; a polymorphism of the MTP promoter report-
edly leads to decreased MTP transcription and a greater
intrahepatocellular triglyceride accumulation, thereby
determining the susceptibility to NASH [35]. The down-
regulation of hepatic MTP activity could lead to a de-
creased visceral fat volume by decreasing the outflow of
lipids from the liver. However, we could not determine
the relation between eNOS and the liver MTP activity in
our study model, and few studies have examined this
point.
eNOS is known to serve important functions, includ-
ing the regulation of vascular tone and regional blood
flow [6]. On the other hand, hepatic tissue blood flow
and hepatic microcirculation have been shown to be
strongly associated with the progression of NAFLD/
NASH [7, 36–38]. In NASH liver, ballooning, which
consists of fat-laden swollen hepatocytes, causes sinus-
oidal distortion, reducing the intrasinusoidal volume and
microvascular blood flow [36–38]. In our eNOS-knock-
out mouse model, while wild-type mice fed an HFD had
a significantly lower hepatic tissue blood flow than the
wild-type mice fed a BD, the eNOS-knockout mice fed a
BD had a significantly lower hepatic blood flow than the
wild-type mice fed a BD. These results suggested that
the decrease in hepatic blood flow in the eNOS-knock-
out mice fed an HFD was not only a secondary effect of
lipid accumulation and compression of the sinusoid, but
was also caused by the eNOS gene deficiency.
Sheldon et al. reported that chronic NOS inhibition via
Nω-nitro-L-arginine methyl ester in obese Otsuka Long-
Evans Tokushima Fatty rats reduced hepatic mitochon-
drial respiration, leading to increased hepatic triacylglyc-
erol accumulation, and increased hepatic inflammation,
although the specific mechanism remained unclear [8].
They did not examine blood flow in the hepatic tissue;
however, the mechanism related to exacerbated early-
stage NAFLD pathogenesis under the condition of eNOS
deficiency might be associated with the function of hepatic
mitochondrial respiration.
Regarding insulin resistance, no significant differences
in systemic insulin resistance, such as the HOMA-IR or
ITT results, were observed between the wild-type and
eNOS-knockout mice under the HFD conditions in this
model. However, direct hepatic insulin responsiveness
was not assessed in this study.
Although the present study revealed a change in the
fat distribution induced by both the eNOS gene and
the HFD in mice in an “early-stage NAFLD/NASH”
model, longer-term analysis may detect a different
phenomenon in “advanced-stage NAFLD/NASH.” A
potential limitation of the current study includes the
use of systemic eNOS-knockout mice. In particular,
Fig. 3 Analysis of hepatic talysis of hepatic tissue blood flow. The
hepatic tissue blood flow measured using a noncontact-type laser
Doppler blood flow meter was significantly lower in the eNOS-/-
mice than in the eNOS+/+ mice under each feeding condition (BD
or HFD) in both hepatic lobes at 12 weeks. The hepatic tissue blood
flow of the eNOS+/+/HFD mice was significantly lower than that of
the eNOS+/+/BD mice. (Data were expressed as the mean ± SEM. *P
< 0.05 represents a significant difference.)
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studies using liver-specific eNOS-knockout mice fed
an HFD or eNOS transgenic mice fed an HFD in a
long-term HFD feeding analysis are needed. Further
studies are needed to verify hepatic mitochondrial res-
piration markers and hepatic inflammation states, and
to examine the relationship between the changes in
hepatic blood flow and the degree of liver injury in
order to determine the exact underlying mechanism.
Conclusions
In conclusion, a deficiency of eNOS-derived NO may
change the fat distributions in the liver and viscera,
thereby promoting the progression of disease in an
HFD-induced, early-stage NASH mouse model by chan-
ging the hepatic tissue blood flow. This report is also the
first study to examine the fat distribution and the patho-
genesis of NAFLD/NASH using an imaging procedure
Fig. 4 Analysis of the mechanism associated with the pathogenesis of NAFLD. a ITT results at 12 weeks showed no significant difference in the
systemic response to insulin injection between the eNOS+/+/HFD mice and the eNOS-/-/HFD mice, while it was significantly lower in the eNOS
+/+/HFD mice than in the eNOS+/+/BD mice, which were regarded as the control group. b The liver SREBP-1c and PPAR-α1 mRNA expression
levels were comparable between the eNOS-/-/HFD mice and the eNOS-/-/HFD mice. The liver MTP activity level was significantly lower in the
eNOS-/-/HFD mice than in the eNOS+/+/HFD mice at 12 weeks. The liver SREBP-1c mRNA expression level and the liver MTP activity level were
significantly higher in the eNOS+/+/HFD mice than in the eNOS+/+/BD mice, which were regarded as the control group. (Data were expressed
as the mean ± SEM. *P < 0.05, represents a significant difference; n.s. represents no significant difference.)
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in an NAFLD/NASH mouse model with or without the
eNOS gene.
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